首页> 外国专利> New polynucleotides encoding proteins involved in spiramycin biosynthesis, useful for improving synthesis of macrolide antibiotics or for generating new hybrid macrolides

New polynucleotides encoding proteins involved in spiramycin biosynthesis, useful for improving synthesis of macrolide antibiotics or for generating new hybrid macrolides

机译：编码参与螺旋霉素生物合成的蛋白质的新多核苷酸，可用于改善大环内酯类抗生素的合成或产生新的杂合大环内酯类

页面导航

摘要
著录项
相似文献

摘要

Polynucleotide (I) that encodes a polypeptide involved in biosynthesis of spiramycin (A) is any of 47 sequences (B) given in the specification, variants (B') of (B), or equivalents of (B) and (B') within the degeneracy of the genetic code. Independent claims are also included for the following: (1) polynucleotides (Ia) that hybridize to (I) under stringent conditions; (2) polynucleotides (Ib) that are at least 70% identical with at least 10 consecutive nucleotides (nt) of (I); (3) polypeptide (II) expressed by (I), (Ia) or (Ib); (4) polypeptides (IIa) involved in synthesis of (A) that have any of 61 sequences (C), reproduced, derivatives (C') of (C) having one or more substitutions, insertions or deletions of amino acids (aa) in (C), and variants of (C) and (C'); (5) polypeptide (IIb) at least 70% identical with at least 10 consecutive aa of (IIa); (6) recombinant DNA (Ic) that contains at least one (I), (Ia) or (Ib); (7) expression vector containing at least one sequence encoding (IIa) or (IIb); (8) expression system comprising vector and host cells able to produce (IIa) or (IIb); (9) host cell containing at least one (I), (Ia), (Ib), (Ic) or the vector of (7); (10) method for producing (IIa) or (IIb); (11) microorganisms (X) blocked in a stage in the biosynthetic pathway of at least one macrolide (M); (12) the Streptomyces ambofaciensstrains CNCM I-2909 or 2911-2917, also SPM510; (13) method for preparing intermediates (MI) in biosynthesis of (M); (14) method for preparing a macrolide derivative (MD) by modification of MI; (15) microorganism (Y) that produces spiramycin I (AI) but not spiramycins II and III; (16) the Streptomyces ambofaciensstrain CNCM I-2910; (17) method for preparing (AI); (18) mutant microorganism (Z) that produces an (M) and has a genetic modification in at least one (I), (Ia) or (Ib) and/or overexpresses such sequences; (19) method for producing (M) by culturing (Z); (20) polynucleotide (Id) that is the complement of (I), (Ia) or (Ib); (21) microorganism (Z1) that produces at least one spiramycin and overexpresses a specific gene (Ie) or its degenerate equivalents; (22) strain S. ambofaciensOSC2/pSPM75(1 or 2), deposited as CNCM I-3101; (23) recombinant DNA (If) amplified from the S. ambofaciensplasmid pSPM36, or its fragments of at least 10 nucleotides; (24) vector containing (If); and (25) method for producing a polypeptide, using the vector of (24). ACTIVITY : Antibacterial; Immunosuppressive; Antirheumatic; Antiarthritic: Anthelmintic; Insecticide. No details of tests for these activities are given. MECHANISM OF ACTION : None given.

机译：编码参与螺旋霉素（A）生物合成的多肽的多核苷酸（I）是说明书中给出的47个序列（B）中的任何一个，（B）的变体（B'）或（B）和（B'）的等价物在遗传密码的简并性之内。还包括以下方面的独立权利要求：（1）在严格条件下与（I）杂交的多核苷酸（Ia）; （2）与（I）的至少10个连续核苷酸（nt）至少70％相同的多核苷酸（Ib）; （3）由（I），（Ia）或（Ib）表达的多肽（II）; （4）具有（A）的合成的多肽（IIa），其具有61个序列（C），已复制的（C）的衍生物（C'），具有氨基酸（aa）的一个或多个取代，插入或缺失（C）中，以及（C）和（C'）的变体; （5）与（IIa）的至少10个连续aa至少70％相同的多肽（IIb）; （6）重组DNA（Ic），其含有至少一个（I），（Ia）或（Ib）; （7）表达载体，其含有至少一个编码（IIa）或（IIb）的序列。（8）表达系统，其包含载体和能够产生（IIa）或（IIb）的宿主细胞; （9）宿主细胞，其含有至少一种（I），（Ia），（Ib），（Ic）或（7）的载体。（10）（IIa）或（IIb）的制造方法; （11）在至少一种大环内酯类（M）的生物合成途径的阶段中被阻断的微生物（X）; （12）链霉菌CNCM I-2909或2911-2917，也为SPM510; （13）（M）的生物合成中的中间体（MI）的制备方法; （14）通过修饰MI制备大环内酯衍生物（MD）的方法。（15）产生螺旋霉素I（AI）但不产生螺旋霉素II和III的微生物（Y）; （16）链霉菌CNCM I-2910; （17）制备方法（AI）; （18）产生（M）并在至少一个（I），（Ia）或（Ib）中具有遗传修饰和/或过表达此类序列的突变微生物（Z）; （19）通过培养（Z）来生产（M）的方法; （20）为（I），（Ia）或（Ib）的补体的多核苷酸（Id）; （21）产生至少一种螺旋霉素并过表达特定基因（Ie）或其简并等价物的微生物（Z1）; （22）菌株S.ambofaciensOSC2 / pSPM75（1或2），保藏为CNCM I-3101; （23）从竹链霉菌pSPM36或其至少10个核苷酸的片段中扩增的重组DNA（If）; （24）包含（If）的向量; （25）使用（24）的载体生产多肽的方法。活性：抗菌;免疫抑制抗风湿;抗关节炎：驱虫药;杀虫剂。没有提供这些活动的测试详细信息。作用机理：未给出。

著录项

公开/公告号FR2851773A1

专利类型
公开/公告日2004-09-03

原文格式PDF
申请/专利权人 AVENTIS PHARMA SA;CENTRE NAT RECH SCIENT;
展开▼

申请/专利号FR20030002439
发明设计人 BLONDELET ROUAULT MARIE HELENE;DOMINGUEZ HELENE;DARBON RONGERE EMMANUELLE;GERBAUD CLAUDE;GONDRAN ANNE;KARRAY FATMA;LACROIX PATRICIA;OESTREICHER MERMET BOUVIER NAT;PERNODET JEAN LUC;TUPHILE KARINE;
展开▼

申请日2003-02-27
分类号C12N15/31;C07K14/36;C12N5/10;C12N9/10;C12N15/52;C12N15/63;C12P19/44;
国家 FR
入库时间 2022-08-21 22:39:13

相似文献

专利
外文文献
中文文献